203 related articles for article (PubMed ID: 34432866)
1. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Lee K; Evans MG; Yang L; Ng S; Snowden C; Khodadoust M; Brown RA; Trum NA; Querfeld C; Doan LT; Song J; Zhang H; Gru AA; Wood GS; Wada DA; Shanmugam V; Haun PL; Aster JC; Duncan LM; Guitart J; Weinstock DM; Nardi V; Choi J
Blood; 2021 Dec; 138(23):2435-2440. PubMed ID: 34432866
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas.
Nicolae A; Xi L; Pham TH; Pham TA; Navarro W; Meeker HG; Pittaluga S; Jaffe ES; Raffeld M
Leukemia; 2016 Nov; 30(11):2245-2247. PubMed ID: 27389054
[No Abstract] [Full Text] [Related]
3. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
Pérez C; González-Rincón J; Onaindia A; Almaráz C; García-Díaz N; Pisonero H; Curiel-Olmo S; Gómez S; Cereceda L; Madureira R; Hospital M; Suárez-Massa D; Rodriguez-Peralto JL; Postigo C; Leon-Castillo A; González-Vela C; Martinez N; Ortiz-Romero P; Sánchez-Beato M; Piris MÁ; Vaqué JP
Haematologica; 2015 Nov; 100(11):e450-3. PubMed ID: 26294736
[No Abstract] [Full Text] [Related]
4. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
Manso R; Sánchez-Beato M; González-Rincón J; Gómez S; Rojo F; Mollejo M; García-Cosio M; Menárguez J; Piris MA; Rodríguez-Pinilla SM
Br J Haematol; 2018 Nov; 183(3):497-501. PubMed ID: 29076126
[No Abstract] [Full Text] [Related]
6. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
7. SnapShot: Jak-STAT Signaling II.
Villarino AV; Gadina M; O'Shea JJ; Kanno Y
Cell; 2020 Jun; 181(7):1696-1696.e1. PubMed ID: 32589961
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and consequences of Jak-STAT signaling in the immune system.
Villarino AV; Kanno Y; O'Shea JJ
Nat Immunol; 2017 Mar; 18(4):374-384. PubMed ID: 28323260
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Lee HJ; Daver N; Kantarjian HM; Verstovsek S; Ravandi F
Clin Cancer Res; 2013 Jan; 19(2):327-35. PubMed ID: 23209034
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT in leukemia: a clinical update.
Liang D; Wang Q; Zhang W; Tang H; Song C; Yan Z; Liang Y; Wang H
Mol Cancer; 2024 Jan; 23(1):25. PubMed ID: 38273387
[TBL] [Abstract][Full Text] [Related]
11. Tools and methods for studying the Drosophila JAK/STAT pathway.
Chen Q; Giedt M; Tang L; Harrison DA
Methods; 2014 Jun; 68(1):160-72. PubMed ID: 24685392
[TBL] [Abstract][Full Text] [Related]
12. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
Waldmann TA; Chen J
Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
[TBL] [Abstract][Full Text] [Related]
13. Inteferons pen the JAK-STAT pathway.
Schindler C; Plumlee C
Semin Cell Dev Biol; 2008 Aug; 19(4):311-8. PubMed ID: 18765289
[TBL] [Abstract][Full Text] [Related]
14. [Molecular components of JAK/STAT signaling pathway and its connection with transcription machinery].
Shaposhnikov AV; Komar'kov IF; Lebedeva LA; Shidlovskiĭ IuV
Mol Biol (Mosk); 2013; 47(3):388-97. PubMed ID: 23888769
[TBL] [Abstract][Full Text] [Related]
15. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
16. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
Shouse G; Nikolaenko L
Curr Hematol Malig Rep; 2019 Dec; 14(6):570-576. PubMed ID: 31741284
[TBL] [Abstract][Full Text] [Related]
17. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
18. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
19. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
20. Biology and significance of the JAK/STAT signalling pathways.
Kiu H; Nicholson SE
Growth Factors; 2012 Apr; 30(2):88-106. PubMed ID: 22339650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
